Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec–(Newsfile Corp. – November 21, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), announces that the holders of the […]
